Form 4: Outlook Therapeutics Director Haddadin Acquires Stock Options

Director Yezan Munther Haddadin acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.

Summary

• On March 7, 2024, Yezan Munther Haddadin, a director of Outlook Therapeutics, Inc., acquired 94,441 stock options.
• The options were granted under the company's 2015 Equity Incentive Plan.
• The exercise price of the options is $0.41.
• The options will fully vest on the earlier of March 7, 2025, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service.
• The options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to continuous service immediately prior to such Change in Control.
• The options expire on March 7, 2034.

Sentiment

Score: 5

Explanation: This is a neutral event, reflecting standard compensation practices. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of management with shareholders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.

Key Dates